Improvement of migratory defects in a murine model of Wiskott-Aldrich syndrome gene therapy.
Wiskott-Aldrich syndrome (WAS) is an X-linked hematological disease characterized by immunodeficiency, eczema, and thrombocytopaenia, and shows promise for treatment with hematopoietic stem cell gene therapy. The immunopathology of WAS is attributable at least in part to defects of cell migration and localization as a result of chemotactic, adhesive, and chemokinetic defects. Whereas previous studies using either gammaretroviral or lentiviral vectors have demonstrated variable correction of T-cell proliferation and dendritic cell (DC) cytoarchitecture, we have used a lentiviral vector expressing an eGFP-WASp fusion protein to test the potential for restoration of cell migratory defects. Multilineage expression of the fusion transgene was present for up to 10 months after primary engraftment, and also in secondary recipients analyzed after a further 9 months. Transduced bone marrow-derived dendritic cells (BMDCs) demonstrated recovery of podosome numbers and turnover, while B cells, BMDCs, and Langerhans cells (LCs) exhibited enhanced chemotactic responses to specific stimuli. As an indication of functionality in vivo, splenic marginal zone B cells and a cutaneous contact hypersensitivity (CHS) response to dinitrofluorobenzene (DNFB) were both partially restored. These proof of principle experiments demonstrate that WAS protein (WASp) transgene expression can be successfully maintained long term in primary and secondary recipients, and that it is associated with a significant repair of migratory defects.
Blundell
Michael P
MP
Molecular Immunology Unit, Wolfson Centre for Gene Therapy of Childhood Disease, University College London Institute of Child Health, London, UK.
Bouma
Gerben
G
Calle
Yolanda
Y
Jones
Gareth E
GE
Kinnon
Christine
C
Thrasher
Adrian J
AJ
D000818:Animals; D002465:Cell Movement; D017690:Cell Transplantation; D002633:Chemotaxis; D003713:Dendritic Cells / Q000166:cytology; D004139:Dinitrofluorobenzene / Q000494:pharmacology; D015316:Genetic Therapy / Q000379:methods*; D049452:Green Fluorescent Proteins / Q000378:metabolism; D007801:Langerhans Cells / Q000166:cytology; D016086:Lentivirus / Q000235:genetics; D051379:Mice; D018345:Mice, Knockout; D008954:Models, Biological; D013154:Spleen; D014923:Wiskott-Aldrich Syndrome / Q000235:genetics* / Q000628:therapy*
D049452:Green Fluorescent Proteins; D004139:Dinitrofluorobenzene